XML 36 R23.htm IDEA: XBRL DOCUMENT v3.20.4
The Company and Summary of Significant Accounting Policies - Additional Information (Detail)
 3 Months Ended 6 Months Ended
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2020
USD ($)
ClinicalTrials
Dec. 31, 2019
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Targeted or Tracking Stock, Stock [Line Items]            
Number of clinical stage candidates | ClinicalTrials     4      
Deferred Revenue Associated With Remaining Performance Obligation $ 84,800,000   $ 84,800,000      
Unrecognized tax benefits 0   0   $ 0  
Revenue Recognised With Performance Obligation 9,100,000 $ 700,000 12,700,000 $ 1,500,000    
Accumulated Losses Since Inception (290,780,000)   (290,780,000)   (277,234,000)  
Cash And Cash Equivalents,Short Term Investments And Common Stock Proceeds Receivable 180,100,000   180,100,000      
Contract assets, Current 10,206,000 481,000 10,206,000 481,000 $ 604,000 $ 686,000
Increase in contract assets     9,602,000 (205,000)    
US License            
Targeted or Tracking Stock, Stock [Line Items]            
Deferred Revenue Associated With Remaining Performance Obligation 64,500,000   64,500,000      
Ex US License            
Targeted or Tracking Stock, Stock [Line Items]            
Deferred Revenue Associated With Remaining Performance Obligation 20,300,000   20,300,000      
Helsinn License Agreement            
Targeted or Tracking Stock, Stock [Line Items]            
Deferred Revenue, Revenue Recognized 100,000 300,000 300,000 700,000    
KKC Commercialization Agreement And The Helsinn License Agreement            
Targeted or Tracking Stock, Stock [Line Items]            
Contract assets, Current 10,200,000   10,200,000      
Increase in contract assets     18,400,000      
KKC Agreements and Helsinn License Agreement            
Targeted or Tracking Stock, Stock [Line Items]            
Contract with Customer, Liability, Revenue Recognized $ 9,200,000 $ 1,000,000 $ 12,700,000 $ 1,800,000